What is the brand name for medroxyprogesterone acetate (MPA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brand Name for Medroxyprogesterone Acetate

The brand name for medroxyprogesterone acetate is Depo-Provera. 1, 2

Formulations Available

Medroxyprogesterone acetate is marketed under the Depo-Provera brand in two distinct formulations for contraceptive use:

  • Depo-Provera (intramuscular): The traditional formulation administered as 150 mg intramuscularly every 3 months (13 weeks) 3, 4

  • Depo-SubQ Provera (subcutaneous): A lower-dose subcutaneous formulation that can be either provider-administered or self-administered, approved more recently with improved tolerability 5, 6

Key Clinical Context

The subcutaneous formulation (DMPA-SC) represents an important advancement, as self-administered DMPA-SC should be made available as an additional approach to deliver injectable contraception according to CDC guidelines, with evidence showing higher continuation rates compared to provider-administered depot medroxyprogesterone acetate 6. Both formulations maintain the same 3-month (13-week) dosing schedule, with injections allowed up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection 6, 7.

The FDA-approved intramuscular formulation is available as 400 mg/mL medroxyprogesterone acetate suspension, though the 150 mg dose is standard for contraceptive use 1. The brand name Depo-Provera has been used worldwide for many decades across more than 90 countries, with over 30 million women having used this contraceptive method 3.

References

Research

Depo-Provera: an injectable contraceptive.

American family physician, 1994

Research

Long-acting injectable contraception with depot medroxyprogesterone acetate.

American journal of obstetrics and gynecology, 1994

Research

Depo Provera. Position paper on clinical use, effectiveness and side effects.

The British journal of family planning, 1999

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Depo Provera Administration and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.